Hans Peter Hasler has served on our Board Since December, 2017. Mr. Hasler was the Chief Executive Officer of Vicarius Pharma AG, a privately held European Bio-Pharma company until 2020. His prior experiences include Elan Corporation, Dublin, where he was Chief Operating Officer, and Biogen Inc., Boston, where his positions included Chief Operating Officer, and EVP, Head of Global Neurology and International. Previously, Mr. Hasler was at Wyeth Pharmaceuticals, Radnor/PA, as Senior Vice President, Chief Marketing Officer and beforehand Managing Director of Wyeth Group Germany, Münster. Mr. Hasler is Chairman of the Board of HBM Healthcare Investments AG in Switzerland (SIX), Chairman of the Board of Shield Therapeutics, London (AIM), and a Director of Gain Therapeutics (Nasdaq). He holds a Federal Swiss Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Business Economy SIB, Zurich.